Roche Pharmaceutical Development and Sales Overview

YTD Sep 2022: Highlights Sales Group sales growth of +2% • Solid Pharma and Diagnostics underlying growth Currency impact on sales • Negative currency impact especially in Q3, particularly weaker EUR and JPY, only partially offset by stronger USD Growth rates at CER (Constant exchange Rates) Roche 44

View entire presentation